ArticleJCEM case reports2026
Drug-induced liver injury due to potassium iodide during thyroid storm.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid storm is a life-threatening condition causing multiorgan failure, including liver dysfunction. Potassium iodide (KI) is one of the key drugs used to control thyroid hormone levels. While thionamides sometimes cause drug-induced liver injury (DILI), KI has not been reported to cause DILI. Herein, we report a case of likely KI-induced DILI during treatment for thyroid storm due to Graves disease. A 30-year-old man presented with thyrotoxicosis due to Graves disease, with hyperbilirubinemia and elevated liver transaminases. The patient was diagnosed with thyroid storm, and treatment was initiated with methimazole, KI, corticosteroids, and beta-blockers. Although the thyroid hormone levels improved during the treatment, total bilirubin levels increased to 32.4 mg/dL (SI: 553 µmol/L) (reference range, <1.2 mg/dL [SI: <20.5 µmol/L]). DILI was suspected, and methimazole was discontinued; however, bilirubin levels remained elevated. Plasma exchange also failed to improve the liver injury. After KI was discontinued, the bilirubin levels rapidly decreased. Lymphocyte transformation tests for methimazole and KI were negative and positive, respectively, confirming the diagnosis of KI-induced DILI. This case highlights that KI should be recognized as a potential cause of DILI in patients with KI therapy who present with abnormal liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.